Dr Marwan Kwok MB ChB, MRCP (UK), PhD, FRCPath

Dr Marwan Kwok

Institute of Cancer and Genomic Sciences
NIHR Clinical Lecturer

Contact details

Institute of Cancer and Genomic Sciences
Institute for Biomedical Research West
Medical School
University of Birmingham
Birmingham B15 2TT

Dr Marwan Kwok is a National Institute for Health Research (NIHR) funded clinical lecturer. He is also a haematologist at Queen Elizabeth Hospital Birmingham. He completed general training in internal medicine, followed by specialist training in haematology, and is a member of the Royal College of Physicians and a fellow of the Royal College of Pathologists. He held a Leukaemia and Lymphoma Research clinical research fellowship from 2014 to 2017 during which he undertook doctoral research training under the mentorship of Professor Tatjana Stankovic and Professor Peter Hillmen. 

His current research focuses on lymphoid malignancies, particularly chronic lymphocytic leukaemia. His research interests include the natural history and clinical heterogeneity of lymphoid malignancies, as well as novel therapeutic targets and minimal residual disease in these conditions. He has authored manuscripts in New England Journal of Medicine, Blood and Leukemia. He was an EHA-ASH Translational Research Training in Hematology (TRTH) 2015 participant, and a past recipient of the UK CLL Forum Hamblin Prize (2016, 2020) and the Royal College of Pathologists specialty research medal (2016, 2020). 

He was recently awarded a 5-year Cancer Research UK Clinician Scientist Fellowship (£1.1M) to commence in March 2022. He will divide his time between Birmingham and Dana-Farber Cancer Institute / Harvard University where he will be based within Professor Catherine J. Wu’s laboratory.   


  • CCT, Certificate of Completion of Training (Haematology), General Medical Council, 2021
  • FRCPath, Fellowship of the Royal College of Pathologists, 2020
  • PhD, Doctor of Philosophy, University of Birmingham, 2018
  • MRCP (UK), Membership of the Royal College of Physicians, 2013
  • MB ChB, Bachelor of Medicine and Bachelor of Surgery, University of Leeds, 2009
  • BSc, Bachelor of Science (with first class honours), University College London, 2006


MB ChB  Year 3 – Clinical Core lecture programme 

BSc Biomedical Sciences Year 3 – Cancer Pathogenesis and Treatment module 

MSc Clinical Oncology – Haemato-oncology module (module co-lead) 

Ad hoc clinical teaching of medical students and junior doctors


Dr Kwok’s research is conducted within the Institute of Cancer and Genomic Sciences at the University of Birmingham, and at the Centre for Clinical Haematology at Queen Elizabeth Hospital. The research is carried out in close collaboration with the Haematological Malignancy Diagnostic Service in Leeds, and with the Centre for Computational Biology in Birmingham. The focus is on translational research with the aim to improve clinical outcome through novel insights into disease biology and therapeutics. Current research themes are as follows: 

1. Natural history and clinical heterogeneity of lymphoid malignancies

2. Novel therapeutic approaches for haematological malignancies and mechanisms of therapeutic resistance

3. Minimal residual disease in lymphoid malignancies

Major external competitive research funding solicited: 

  • Cancer Research UK Clinician Scientist Fellowship (2022-2027) - Identifying tumour-immune interactions as determinants of clinical sequelae in chronic lymphocytic leukaemia (£1,052,397) 
  • Leukaemia and Lymphoma Research Clinical Research Training Fellowship (2014-2017) - Evaluation of novel therapeutic approaches in chronic lymphocytic leukaemia to eradicate resistant subclones with DNA damage response defects (£258,549)

The research groups and centres that Dr Kwok has involvement with can be found at the following links:


Kwok M, Oldreive C, Rawstron AC, Goel A, Papatzikas G, Jones RE, Drennan S, Agathanggelou A, Sharma-Oates A, Evans P, Smith E, Dalal S, Mao J, Hollows R, Gordon N, Hamada M, Davies N, Parry H, Beggs AD, Munir T, Moreton P, Paneesha S, Pratt G, Taylor AMR, Forconi F, Baird DM, Cazier JB, Moss P, Hillmen P, Stankovic T. Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL. Blood. 2020; 135:411-428 

Kwok M, Rawstron AC, Varghese A, Evans PAS, O’Connor SJM, Doughty C, Newton DK, Moreton P, Hillmen P. Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood. 2016; 128:2770-2773

Kwok M, Davies N, Agathanggelou A, Smith E, Oldreive C, Petermann E, Stewart G, Brown J, Lau A, Pratt G, Parry H, Taylor M, Moss P, Hillmen P, Stankovic T. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53 or ATM defective chronic lymphocytic leukemia cells. Blood. 2016; 127:582-595

Kwok M, Wu CJ. Clonal evolution of high-risk chronic lymphocytic leukemia: a contemporary perspective. Frontiers in Oncology. 2021; 11:790004

Stankovic T, Kwok M. Ibrutinib: another string to its bow. Blood. 2021; 137:3461-3462

Kwok M, Agathanggelou A, Davies N, Stankovic T. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers. 2021; 13:4681

Kwok M, Fritsch EF, Wu CJ. Cancer and COVID-19: on the quest for effective vaccines. Blood Cancer Discovery. 2021; 2:13-18

Stankovic T, Kwok M. Genetics in the era of targeted CLL therapy. Blood. 2020; 135:2333-2334 

Parry HM, Mirajkar N, Cutmore N, Zuo J, Long H, Kwok M, Oldrieve C, Hudson C, Stankovic T, Paneesha S, Kelly M, Begum J, McSkeane T, Pratt G, Moss P. Long-term ibrutinib therapy reverses CD8+ T cell exhaustion in B cell chronic lymphocytic leukaemia. Front. Immunol. 2019; 10:2832

Oldreive CE, Byrd PJ, Stewart GS, Taylor AJ, Farhat S, Skowronska A, Smith E, Raghavan M, Janic D, Dokmanovic L, Clokie S, Davies N, Kwok M, Pratt G, Paneesha S, Moss P, Stankovic T, Taylor M. PALB2 variant status in hematological malignancies - a potential therapeutic target? Leuk Lymphoma. 2019; 7:1-4

Agathanggelou A, Smith E, Davies NJ, Kwok M, Zlatanou A, Oldreive CE, Mao J, Da Costa D, Yadollahi S, Perry T, Kearns P, Skowronska A, Yates E, Parry H, Hillmen P, Reverdy C, Delansorne R, Paneesha S, Pratt G, Moss P, Taylor AMR, Stewart GS, Stankovic T. USP7 inhibition alters homologous recombination repair and targets CLL cells independent of ATM/p53 functional status. Blood. 2017; 130:156-166

Davies NJ, Kwok M, Gould C, Oldreive CE, Mao J, Parry H, Smith E, Agathanggelou A, Pratt G, Taylor AMR, Moss P, Griffiths M, Stankovic T. Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts. Oncotarget. 2017; 8:44749-44760

Rawstron AC, Bennett F, O’Connor SJM, Kwok M, Fenton JAL, Plummer M, Tute R, Richards SJ, Jack AS, Hillmen P. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. New Engl J Med. 2008; 359:575-583

Chuah C, Barnes DJ, Kwok M, Corbin A, Deininger MWN, Druker BJ, Melo JV. Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukemic cells. Leukemia. 2005; 19:1896-1904

Kwok M, Stankovic T. Targeting the Ataxia Telangiectasia and Rad3 Signaling Pathway to Overcome Chemoresistance in Cancer. In Johnson DE (ed), Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Elsevier Publishing Company. 2019; p. 204-231

Kwok M, Stankovic T. Targeting replication stress in sporadic tumors. In Grand RJ (ed), DNA Replication and Double Strand Break Repair: Mechanisms and Clinical Significance. 2018; Garland Science; p. 329-337

View all publications in research portal